Trials / Completed
CompletedNCT04682119
A Safety Study of LY3526318 in Healthy Participants
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to learn more about how the drug is absorbed in to the blood stream and how it is eliminated from the body. The safety and tolerability of LY3526318 will also be evaluated when given by mouth either by single or multiple doses to healthy participants. The study will have two parts. Each participant will enroll in only one part. For each participant, Part A will last up to 44 days and Part B will last up to 50 days, including screening and follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3526318 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2020-12-29
- Primary completion
- 2021-04-21
- Completion
- 2021-04-21
- First posted
- 2020-12-23
- Last updated
- 2025-09-10
- Results posted
- 2025-09-10
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04682119. Inclusion in this directory is not an endorsement.